Nara K, Yamamoto T, Yamashita H, Yagi K, Takada T, Seto Y
BMC Cancer. 2023; 23(1):979.
PMID: 37833660
PMC: 10571405.
DOI: 10.1186/s12885-023-11469-y.
Li Y, Drabison T, Nepal M, Ho R, Leblanc A, Gibson A
JCI Insight. 2023; 8(14).
PMID: 37347545
PMC: 10443802.
DOI: 10.1172/jci.insight.164646.
Klein I, Isensee J, Wiesen M, Imhof T, Wassermann M, Muller C
Cells. 2023; 12(9).
PMID: 37174648
PMC: 10177491.
DOI: 10.3390/cells12091249.
Talebi Z, Sparreboom A, Colace S
Methods Mol Biol. 2022; 2547:63-94.
PMID: 36068461
DOI: 10.1007/978-1-0716-2573-6_4.
Horiuchi M, Uemura T, Oguri T, Toda S, Yamamoto S, Suzuki Y
Invest New Drugs. 2022; 40(5):934-943.
PMID: 35759133
DOI: 10.1007/s10637-022-01275-x.
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.
Hertz D
Expert Opin Drug Metab Toxicol. 2021; 17(2):227-239.
PMID: 33401943
PMC: 7864890.
DOI: 10.1080/17425255.2021.1856367.
Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.
Anderson J, Huang K, Lustberg M, Sparreboom A, Hu S
Rev Physiol Biochem Pharmacol. 2020; 183:177-215.
PMID: 32761456
PMC: 7902122.
DOI: 10.1007/112_2020_30.
Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients.
Wang Z, Zhang N, Chen C, Chen S, Xu J, Zhou Y
Curr Drug Metab. 2019; 20(7):592-600.
PMID: 31267867
PMC: 6857112.
DOI: 10.2174/1389200220666190701094756.
Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure.
Fujita K, Matsumoto N, Ishida H, Kubota Y, Iwai S, Shibanuma M
Curr Drug Metab. 2019; 20(5):361-376.
PMID: 30947665
PMC: 6700602.
DOI: 10.2174/1389200220666190402143125.
Characterization of ADME genes variation in Roma and 20 populations worldwide.
Skaric-Juric T, Tomas Z, Zajc Petranovic M, Bozina N, Narancic N, Janicijevic B
PLoS One. 2018; 13(11):e0207671.
PMID: 30452466
PMC: 6242375.
DOI: 10.1371/journal.pone.0207671.
OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.
Leblanc A, Sprowl J, Alberti P, Chiorazzi A, Arnold W, Gibson A
J Clin Invest. 2018; 128(2):816-825.
PMID: 29337310
PMC: 5785270.
DOI: 10.1172/JCI96160.
Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.
Stage T, Bergmann T, Kroetz D
Clin Pharmacokinet. 2017; 57(1):7-19.
PMID: 28612269
PMC: 8572663.
DOI: 10.1007/s40262-017-0563-z.
Renal Drug Transporters and Drug Interactions.
Ivanyuk A, Livio F, Biollaz J, Buclin T
Clin Pharmacokinet. 2017; 56(8):825-892.
PMID: 28210973
DOI: 10.1007/s40262-017-0506-8.
Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.
Stewart D, Winnike J, McRitchie S, Clark R, Pathmasiri W, Sumner S
J Proteome Res. 2016; 15(9):3225-40.
PMID: 27447733
PMC: 5034715.
DOI: 10.1021/acs.jproteome.6b00430.
Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy.
Thakkar N, Lockhart A, Lee W
AAPS J. 2015; 17(3):535-45.
PMID: 25735612
PMC: 4406968.
DOI: 10.1208/s12248-015-9740-x.
Pharmacogenetics of membrane transporters: a review of current approaches.
Sissung T, Goey A, Ley A, Strope J, Figg W
Methods Mol Biol. 2014; 1175:91-120.
PMID: 25150868
PMC: 6388404.
DOI: 10.1007/978-1-4939-0956-8_6.
Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression.
Cho E, Montgomery R, Mostaghel E
Endocrinology. 2014; 155(11):4124-32.
PMID: 25147980
PMC: 4298565.
DOI: 10.1210/en.2014-1337.
Influence of drug formulation on OATP1B-mediated transport of paclitaxel.
Nieuweboer A, Hu S, Gui C, Hagenbuch B, Ghobadi Moghaddam-Helmantel I, Gibson A
Cancer Res. 2014; 74(11):3137-45.
PMID: 24755470
PMC: 4161133.
DOI: 10.1158/0008-5472.CAN-13-3634.
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.
Godoy P, Hewitt N, Albrecht U, Andersen M, Ansari N, Bhattacharya S
Arch Toxicol. 2013; 87(8):1315-530.
PMID: 23974980
PMC: 3753504.
DOI: 10.1007/s00204-013-1078-5.
The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro.
Tsakalozou E, Adane E, Kuo K, Daily A, Moscow J, Leggas M
Drug Metab Dispos. 2013; 41(7):1404-13.
PMID: 23620484
PMC: 3684821.
DOI: 10.1124/dmd.112.050021.